• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • BMS talks up Celgene merger to divert Opdivo disappointment fiercepharma
    January 28, 2019
    In the wake of bad news from its closely watched immuno-oncology portfolio, Bristol-Myers Squibb executives did their best Thursday to talk up the six near-term product launches they’re expecting from the company's $74 billion merger with Celgene. But the

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service